Evidence map›Paper›PMID 41929475›Full record

Trial reportFrontiers in immunology2025

Neuronal autoantibodies associated with poorer neuropsychological and motor outcomes 6 months after stroke: results from the PHYS-STROKE trial.

Charlotte Pietrock, Konrad Neumann, Kristin Rentzsch, Harald Prüss, Andreas Meisel, Matthias Endres, Alexander Heinrich Nave

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01953549 (Physical Fitness Training in Subacute Stroke), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01953549 phase3completednot on this map

Physical Fitness Training in Subacute Stroke (PHYS-Stroke)

TypeinterventionalSponsorCharite University, Berlin, GermanyRan2013 to 2017Enrolled200ConditionsStrokeArmsphysical fitness training, relaxation
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Charlotte PietrockCenter for Stroke Research Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Konrad NeumannInstitute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Kristin RentzschClinical Immunological Laboratory Prof. h.c. (RCH) Dr. med. Winfried Stöcker, Groß Grönau, Germany.
Harald PrüssDepartment of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, Humboldt-Universität zu, and Berlin Institute of Health, Berlin, Germany.
Andreas MeiselDepartment of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, Humboldt-Universität zu, and Berlin Institute of Health, Berlin, Germany.
Matthias EndresDepartment of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, Humboldt-Universität zu, and Berlin Institute of Health, Berlin, Germany.
Alexander Heinrich NaveDepartment of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, Humboldt-Universität zu, and Berlin Institute of Health, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Emerging evidence suggests a role of neuronal autoantibodies (nAbs) for long-term stroke outcomes. However, data remain limited and many domains unexamined. We present a comprehensive analysis of nAbs and their association with a broad range of outcome measures at multiple timepoints in the six months following moderate stroke. Methods: In this explorative analysis of the multicenter, randomized-controlled Results: Two hundred stroke patients (41% female; mean age: 69 ± 12 years, median acute National Institutes of Health Stroke Scale: 8) were enrolled. Cell-based seroreactivity decreased from baseline to six months (39 of 183 patients [21%] Conclusions: Antibody seropositivity was associated with poorer outcomes in certain neuropsychological and motor outcome measures at six but not three months post-stroke. These findings require confirmation in larger cohorts and emphasize the need for future studies with longer follow-up periods in this patient population. Trial registration: clinicaltrials.gov NCT01953549.

Indexed as

AutoantibodiesNeuronsStrokeAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPrognosisRecovery of FunctionAutoantibodiesBiomarkersbiomarkerneuroimmunologyneuronal autoantibodiesNMDARoutcomerecoverystroke

Identifiers

PMID41929475
PMCPMC13038563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.